NCT06386744View on ClinicalTrials.gov

Dusquetide for the Treatment of Behcet's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 18, 2024

Primary Completion Date

May 23, 2025

Study Completion Date

June 17, 2025

Conditions

Behçet Disease

Interventions

DRUG

Dusquetide

1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks

Trial Locations (1)

Unknown

Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine, Istanbul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Soligenix

INDUSTRY